Lipid Nanostructures as Drug Carriers for Cancer Therapy
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".
Deadline for manuscript submissions: 20 December 2024 | Viewed by 720
Special Issue Editor
Interests: nanotechnology; cancer; nanostructures; biochemistry
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Cancer constitutes a major cause of death worldwide, and the prevailing pharmacotherapies frequently cause debilitating adverse effects. In recent decades, various therapeutic modalities have emerged to address these issues, including immunotherapy, tailored precision chemotherapy, and nanomedicine. Notably, the utilization of nanostructures has demonstrated considerable potential in enhancing both drug biodistribution and their interactions with target cells, thereby offering prospects for improved outcomes in cancer therapy. Among the myriad of nanostructures proposed in the scientific literature, lipid-based formulations have exhibited superior performance and biocompatibility. Furthermore, the diverse range of human-compatible lipids has empowered researchers to fabricate an expansive repertoire of lipid nanostructures endowed with distinctive attributes, such as sustained drug release and prolonged circulation times. This Special Issue is dedicated to elucidating the latest advancements in lipid nanostructures engineered as drug carriers for cancer therapeutics.
Prof. Dr. Luís Alexandre Muehlmann
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer
- lipid nanostructures
- nanomedicine
- nanotechnology
- chemotherapy
- immunotherapy
